JB Chemicals & Pharmaceuticals Limited (JBCPL), one of the fastest growing pharmaceutical companies in India, has announced that it will acquire brands for the Indian market from Sanzyme Private Limited (Sanzyme), a leading player in the probiotics and reproductive health segment in the country.
The transaction is valued at Rs. 628 crore and is expected to be completed in the next two weeks subject to customary closing formalities.
Sanzyme, ranked amongst the top five probiotics players in the country, is engaged in the manufacture, distribution and marketing of specialty probiotics formulations, infertility management products and nutraceuticals products. It operates in the gastroenterology, nephrology, urology and gynaecology therapy areas with leading brands such as Sporlac, Lobun, and Gynogen. As per IQVIA MAT December 21 data, the revenue for the combined brands was Rs. 160 crore
